Tag: Bioxyne Limited
Bioxyne signs $5.6M supply agreement to enter German medical cannabis market
Bioxyne Limited), through its subsidiary Breathe Life Sciences (BLS), has entered the German medical cannabis market by securing a commercial supply agreement worth a minimum of €3.2 million (approximately AUD 5.6 million) for FY2026.
Bioxyne granted Australia’s first GMP licence for Psilocybin and MDMA manufacturing
Bioxyne Limited's subsidiary, Breathe Life Sciences (BLS), has secured the Good Manufacturing Practice (GMP) licence for the production of medical cannabis.
Featured Article
GridBeyond highlights role of technology in navigating energy market swings
Energy price volatility continues to pose challenges for manufacturers and other energy-intensive industries, particularly as electricity markets experience more frequent and unpredictable price swings.
